Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, which will enhance its presence in the high-value medical device market for orthopedics and ophthalmology [1] Group 1 - The acquisition will be completed in three phases between 2025 and 2026, with total cash consideration of RMB 38,351,487.36 for Buyer I and RMB 4,755,979.05 for Buyer II [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury repair, and tear duct obstruction support [1] - By investing in the target company, the group aims to enter the high-value biological amniotic membrane market, complementing its existing product portfolio and expanding its business layout in orthopedics and ophthalmology [1] Group 2 - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in regenerative medicine and tissue engineering [1] - This investment is expected to drive subsequent product innovation and technological upgrades within the group [1]
昊海生物科技分三阶段收购江西瑞济生物19.8%股权 总对价约3835万元